Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial

@inproceedings{Sarwar2014HomologousBW,
  title={Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial},
  author={Uzma N Sarwar and Laura Novik and Mary E. Enama and Sarah A. Plummer and Richard A. Koup and Martha C. Nason and Robert T. Bailer and Adrian B McDermott and Mario Roederer and John R. Mascola and Julie E. Ledgerwood and Barney S. Graham and Thomas L. Richie},
  booktitle={PloS one},
  year={2014}
}
BACKGROUND Needle-free delivery improves the immunogenicity of DNA vaccines but is also associated with more local reactogenicity. Here we report the first comparison of Biojector and needle administration of a candidate rAd5 HIV vaccine. METHODS Thirty-one adults, 18-55 years, 20 naive and 11 prior rAd5 vaccine recipients were randomized to receive single rAd5 vaccine via needle or Biojector IM injection at 1010 PU in a Phase I open label clinical trial. Solicited reactogenicity was… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.

The Journal of infectious diseases • 2006
View 4 Excerpts
Highly Influenced

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

The New England journal of medicine • 2013
View 1 Excerpt

induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial

BS Graham, ME Enama, MC Nason, IJ Gordon, SA Peel
2013